Summary: Pediatric patients with parameningeal rhabdomyosarcoma and high-risk features are recommended to receive radiotherapy at initiation of protocol therapy due to concerns about the increased risk of local and leptomeningeal failure from treatment delay. We report our early experience on a multi-institutional prospective trial incorporating delayed primary site radiation and reduced dose cyclophosphamide in all patients with parameningeal tumors. We observed an excessive number of locoregional treatment failures following this approach and have subsequently amended our trial to move radiation therapy upfront for those patients with high-risk features. We suggest that investigators should be vigilant for treatment failure given our early prospective experience with delayed radiotherapy and reduced dose cyclophosphamide.
Summary: Pediatric patients with parameningeal rhabdomyosarcoma and high-risk features are recommended to receive radiotherapy at initiation of protocol therapy due to concerns about the increased risk of local and leptomeningeal failure from treatment delay. We report our early experience on a multi-institutional prospective trial incorporating delayed primary site radiation and reduced dose cyclophosphamide in all patients with parameningeal tumors. We observed an excessive number of locoregional treatment failures following this approach and have subsequently amended our trial to move radiation therapy upfront for those patients with high-risk features. We suggest that investigators should be vigilant for treatment failure given our early prospective experience with delayed radiotherapy and reduced dose cyclophosphamide. In 2013 we initiated a prospective multi-institutional study in children with newly diagnosed RMS evaluating the use of combination chemotherapy, proton beam radiation therapy, upfront or delayed primary surgical resection and maintenance anti-angiogenic therapy. The study incorporated delayed radiation therapy (week 12) for all patients requiring radiation including all patients with PM primary sites of disease in order to reduce the late effects associated with irradiation of large volumes of the head and neck region in young children 5 that have not had the benefit of chemo-reduction of their disease. During this study we identified an excessive risk of locoregional failure (primary site recurrence or leptomeningeal spread) requiring a return to early initiation of radiation therapy in patients with PM primary tumors and high-risk features. We report these findings and outcomes for subsequent patients with PM primaries in this ongoing trial.
METHODS AND MATERIALS
RMS13 is a risk adapted multimodality therapeutic trial, which treats patients with newly diagnosed RMS according to their initial risk assignment. Initially low-risk and intermediate-risk patients were enrolled and receive 12 weeks of (vincristine, 1.5 mg/m 2 ; actinomycin, 0.045 mg/kg; and cyclophosphamide, 1.2 g/m 2 ) chemotherapy followed by 12 weeks of VA chemotherapy (Low risk subset 1) or 42 weeks of vincristine, actinomycin, and cyclophosphamide chemotherapy (low-risk subset 2 and intermediate-risk patients). High-risk patients, added to the trial in 2015, receive 54 weeks of interval compressed chemotherapy (vincristine, dactinomycin, cyclophosphamide, irinotecan, ifosfamide, etoposide, and doxorubicin). Intermediate-risk and high-risk patients receive additional maintenance therapy (anti-angiogenic chemotherapy incorporating bevacizumab, sorafenib, and low-dose cyclophosphamide) after completion of cytotoxic chemotherapy.
At the initiation of the trial all patients, including all patients with PM disease regardless of PM features, received radiation therapy at week 13 for involved margins or an unresected primary tumor. The residual postchemotherapy gross disease is targeted with a 0.5 cm margin and this volume, plus tissue that initially harbored gross disease (specifically bone or other "infiltrated" tissues) is treated to a dose of 36 cobalt grey equivalent (CGE) with proton beam. A "cone-down" is utilized to treat residual postchemotherapy gross disease to doses of 50.4 CGE (tumors ≤ 5 cm at diagnosis) or 59.4 CGE (tumors > 5 cm at diagnosis).
RESULTS
The characteristics and outcomes of all PM patients currently enrolled are shown in Table 1 . As of (October 2017) there are 13 patients with intermediate-risk or high-risk disease and PM primaries whose age ranged from 3 to 21 years. Four patients were treated before amending the study and changing the timing of radiation therapy and 9 have been treated since the amendment (median follow-up on study of 9.9 and 9.3 mo, respectively). The first 3 patients with PM primary sites of disease that were treated on this trial either progressed locally before RT or recurred with leptomeningeal disease following delayed RT at 1.6, 7.2 and 12.5 months from start of therapy. A fourth patient that was under treatment had RT moved earlier and received it at week 6 and is alive without recurrence. These 4 patients all had high-risk features of PM disease including large tumor size, cranial base, and bone erosion or ICE. Following this initial experience on this trial we amended the protocol to move radiation therapy upfront (day 21) for patients with PM disease with high-risk features 2 including any of the following: (1) ICE or evidence of meningeal impingement, cranial nerve palsies, or base of skull erosion; (2) tumor location in an unfavorable PM site (infratemporal fossae, pterygopalatine fossae, or paranasal sinuses), (3) primary tumor > 5 cm in 1 dimension, or (4) age <1 year at diagnosis. Since that change in protocol therapy we have accrued an additional 9 intermediate-risk and high-risk patients with PM RMS, 7 of which had high-risk PM features necessitating RT upfront, and have documented 2 regional recurrences in the leptomeninges (2.9 and 6.4 mo from initiation of therapy) and no local recurrences (Figs. 1, 2) .
DISCUSSION
The vast majority of RMS trials that have been conducted by the Children's Oncology Group have prescribed RT to the primary site by week 13 unless the patient had a PM primary tumor site with high-risk features in which case RT would be initiated early. The criteria for selecting PM patients for early RT has mostly been based on criteria that adversely increase the risk of failure such as age <1 year, Cranial Nerve Palsy, cranial base bone erosion, ICE, size > 5 cm and unfavorable site. 2, 6, 7 Others have proposed response to chemotherapy as a modifying factor for target volume reductions, 8 although this strategy for altering RT timing is untested. 9 Smaller studies have successfully delayed or omitted RT with adequate local control rates when patients received more intensive chemotherapies. 3, 4, 10 Our findings suggest that local control rates may be compromised in selected patients with PM tumors when RT is delayed and given with lower doses of cyclophosphamide (1.2 g/m 2 ). Reduced doses of cyclophosphamide have been recently implicated as a factor that contributes to higher local failure rates in children with group III vaginal and orbital RMS 11, 12 in recent studies in lower risk subsets of RMS. 11 The contribution of limited RT target margins cannot be excluded 8 but prior studies have demonstrated no decrement with reductions in target volume with leptomeningeal failure rate. 1 By starting at a delayed time point, a larger proportion of the at risk tumor bed from 
